Table 6.
Results of the sensitivity scenarios
| Method | Costs | Incremental costs | Effectiveness (QALYs) | Incremental Effectiveness | ICER | |
|---|---|---|---|---|---|---|
| Excluding data for metabolic acidosis in the trial by Ojala et al.4 | ST analysis | €3308 | −€115 | 27.1660 | 0.0092 | Dominating |
| CTG | €3423 | 27.1568 | ||||
| 25-year time horizon | ST analysis | €2800 | −€37 | 16.4671 | 0.0033 | Dominating |
| CTG | €2837 | 16.4638 | ||||
| Including two extra cases of metabolic acidosis in the ST analysis arm | ST analysis | €3357 | −€49 | 27.1630 | 0.0048 | Dominating |
| CTG | €3405 | 27.1582 | ||||
| Excluding production losses for individuals with severe cerebral palsy | ST analysis | €3120 | −€48 | 27.1636 | 0.0054 | Dominating |
| CTG | €3168 | 27.1582 | ||||
| Using data on encephalopathy from the Swedish RCT24 | ST analysis | €2363 | −€228 | 27.1682 | 0.0291 | Dominating |
| CTG | €2592 | 27.1973 | ||||
| Augmenting the costs of severe cerebral palsy with 50% | ST analysis | €3823 | −€73 | 27.1636 | 0.0054 | Dominating |
| CTG | €3896 | 27.1582 | ||||
| Decreasing the costs of severe cerebral palsy with 50% | ST analysis | €2874 | −€40 | 27.1636 | 0.0054 | Dominating |
| CTG | €2914 | 27.1582 |